Literature DB >> 24925587

Vaccinations for rheumatoid arthritis.

Lisa M Perry1, Kevin L Winthrop, Jeffrey R Curtis.   

Abstract

Patients with rheumatoid arthritis (RA) suffer an increased burden of infectious disease-related morbidity and mortality and have twice the risk of acquiring a severe infection compared to the general population. This increased risk is not only a result of the autoimmune disease but is also attributed to the immunosuppressive therapies that are commonly used in this patient population. Given the increase in infection-related risks in RA, there is great interest in mitigating such risk. A number of vaccines are available to the rheumatologist, with a handful that are of importance for RA patients in the United States. The goal of this paper is to highlight the most recent literature on the key vaccines and the specific considerations for the rheumatologist and their RA patients, with a particular focus on influenza, pneumococcal, and herpes zoster vaccines. It is important for rheumatologist to understand and be aware of which vaccines are live and what potential contraindications exist for giving vaccines to RA patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24925587      PMCID: PMC4080407          DOI: 10.1007/s11926-014-0431-x

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  44 in total

1.  Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers.

Authors:  I Fomin; D Caspi; V Levy; N Varsano; Y Shalev; D Paran; D Levartovsky; I Litinsky; I Kaufman; I Wigler; E Mendelson; O Elkayam
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

2.  Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.

Authors:  Jeffrey L Kaine; Alan J Kivitz; Charles Birbara; Allison Y Luo
Journal:  J Rheumatol       Date:  2007-02       Impact factor: 4.666

3.  Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response.

Authors:  S Oren; M Mandelboim; Y Braun-Moscovici; D Paran; J Ablin; I Litinsky; D Comaneshter; D Levartovsky; E Mendelson; R Azar; I Wigler; A Balbir-Gurman; D Caspi; O Elkayam
Journal:  Ann Rheum Dis       Date:  2007-11-02       Impact factor: 19.103

4.  Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity.

Authors:  S Salemi; A Picchianti-Diamanti; V Germano; I Donatelli; A Di Martino; M Facchini; R Nisini; R Biselli; C Ferlito; E Podestà; A Cappella; F Milanetti; F Rossi; R Amodeo; F Tabacco; R Di Rosa; B Laganà; R D Amelio
Journal:  Clin Immunol       Date:  2009-10-21       Impact factor: 3.969

5.  Improved influenza and pneumococcal vaccination in rheumatology patients taking immunosuppressants using an electronic health record best practice alert.

Authors:  Lindsay J Ledwich; Thomas M Harrington; William T Ayoub; Jennifer A Sartorius; Eric D Newman
Journal:  Arthritis Rheum       Date:  2009-11-15

6.  The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination.

Authors:  L B S Gelinck; A E van der Bijl; W E P Beyer; L G Visser; T W J Huizinga; R A van Hogezand; G F Rimmelzwaan; F P Kroon
Journal:  Ann Rheum Dis       Date:  2007-10-26       Impact factor: 19.103

7.  Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Rafael Harpaz; Ismael R Ortega-Sanchez; Jane F Seward
Journal:  MMWR Recomm Rep       Date:  2008-06-06

Review 8.  Vaccination in patients with chronic rheumatic or autoimmune diseases.

Authors:  T Glück; U Müller-Ladner
Journal:  Clin Infect Dis       Date:  2008-05-01       Impact factor: 9.079

9.  Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.

Authors:  Sander van Assen; Albert Holvast; Cornelis A Benne; Marcel D Posthumus; Miek A van Leeuwen; Alexandre E Voskuyl; Marlies Blom; Anke P Risselada; Aalzen de Haan; Johanna Westra; Cees G M Kallenberg; Marc Bijl
Journal:  Arthritis Rheum       Date:  2010-01

10.  Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

Authors:  Clifton O Bingham; R John Looney; Atul Deodhar; Neal Halsey; Maria Greenwald; Christine Codding; Benjamin Trzaskoma; Flavius Martin; Sunil Agarwal; Ariella Kelman
Journal:  Arthritis Rheum       Date:  2010-01
View more
  10 in total

Review 1.  Vaccine-Drug Interactions: Cytokines, Cytochromes, and Molecular Mechanisms.

Authors:  Paolo Pellegrino; Cristiana Perrotta; Emilio Clementi; Sonia Radice
Journal:  Drug Saf       Date:  2015-09       Impact factor: 5.606

Review 2.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

Review 3.  Secondary Causes of Myositis.

Authors:  Sarah H Berth; Thomas E Lloyd
Journal:  Curr Treat Options Neurol       Date:  2020-10-06       Impact factor: 3.598

4.  Incidence, mortality, and national costs of hospital admissions for potentially preventable infections in patients with rheumatoid arthritis.

Authors:  Joanna Potera; Soumyasri Kambhatla; Estefania Gauto-Mariotti; Augustine Manadan
Journal:  Clin Rheumatol       Date:  2021-07-12       Impact factor: 2.980

5.  The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial.

Authors:  Yasumori Izumi; Manabu Akazawa; Yukihiro Akeda; Shigeto Tohma; Fuminori Hirano; Haruko Ideguchi; Ryutaro Matsumura; Tomoya Miyamura; Shunsuke Mori; Takahiro Fukui; Nozomi Iwanaga; Yuka Jiuchi; Hideko Kozuru; Hiroshi Tsutani; Kouichirou Saisyo; Takao Sugiyama; Yasuo Suenaga; Yasumasa Okada; Masao Katayama; Kenji Ichikawa; Hiroshi Furukawa; Kenji Kawakami; Kazunori Oishi; Kiyoshi Migita
Journal:  Arthritis Res Ther       Date:  2017-01-25       Impact factor: 5.156

6.  The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.

Authors:  Kevin L Winthrop; Ann G Wouters; Ernest H Choy; Koshika Soma; Jennifer A Hodge; Chudy I Nduaka; Pinaki Biswas; Elie Needle; Sherry Passador; Christopher F Mojcik; William F Rigby
Journal:  Arthritis Rheumatol       Date:  2017-09-06       Impact factor: 10.995

7.  Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.

Authors:  Jin Kyun Park; Yun Jong Lee; Kichul Shin; You-Jung Ha; Eun Young Lee; Yeong Wook Song; Yunhee Choi; Kevin L Winthrop; Eun Bong Lee
Journal:  Ann Rheum Dis       Date:  2018-03-23       Impact factor: 19.103

8.  Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy.

Authors:  Kevin L Winthrop; Clifton O Bingham; Wendy J Komocsar; John Bradley; Maher Issa; Rena Klar; Cynthia E Kartman
Journal:  Arthritis Res Ther       Date:  2019-04-18       Impact factor: 5.156

9.  Efficient ex vivo analysis of CD4+ T-cell responses using combinatorial HLA class II tetramer staining.

Authors:  Hannes Uchtenhagen; Cliff Rims; Gabriele Blahnik; I-Ting Chow; William W Kwok; Jane H Buckner; Eddie A James
Journal:  Nat Commun       Date:  2016-08-30       Impact factor: 14.919

10.  When treating rheumatoid arthritis be vigilant for influenza (& pneumonia): Don't ignore, don't neglect.

Authors:  Arvind Chopra; Vaijayanti Lagoo Joshi
Journal:  Indian J Med Res       Date:  2017-04       Impact factor: 2.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.